Parkinson’s Therapy May Hold Promise for Fragile X

Parkinson’s Therapy May Hold Promise for Fragile X

287558

Parkinson’s Therapy May Hold Promise for Fragile X

Treatment with istradefylline — an approved therapy for Parkinson’s disease — normalized several molecular and functional nerve cell features of fragile X syndrome and improved cognitive skills in a mouse model of the disease, a study shows. The therapy, sold by Kyowa Hakko Kirin Pharma under the brand name Nourianz, works by suppressing the activity of adenosine A2A receptors (A2AARs), proteins known to tightly control the overly active activity of a nerve cell receptor in fragile X patients.…

You must be logged in to read/download the full post.